Hepatitis C causes chronic liver inflammation that can lead to scarring (fibrosis), advanced scarring (cirrhosis), liver failure, and hepatocellular carcinoma. Left untreated, it progresses silently in most people, often causing irreversible damage before symptoms appear.
The hepatitis C virus (HCV) targets liver cells, triggering persistent immune activation. This leads to ongoing tissue injury. Over 20 years, approximately 15-30% of infected individuals develop cirrhosis, according to the Centers for Disease Control and Prevention (CDC). The progression varies by individual factors such as age at infection, alcohol use, coexisting conditions like HIV or fatty liver disease, and viral genotype.
Chronic hepatitis C is responsible for nearly half of all liver-related deaths in the United States. The American Liver Foundation reports that HCV is the leading cause of liver transplantation in adults. Without treatment, the virus remains active in the bloodstream, continuously damaging liver tissue and increasing the risk of complications.
When HCV enters the body, it infects hepatocytes-the primary functional cells of the liver. The immune system responds by sending inflammatory cells to eliminate the virus. But this response also damages healthy liver tissue. Repeated cycles of infection and immune attack result in fibrosis, where scar tissue replaces normal liver structure.
Fibrosis impairs blood flow through the liver and reduces its ability to detoxify substances, produce proteins, and metabolize drugs. As scarring worsens, the liver loses function. Once cirrhosis develops, the liver's architecture is permanently altered. The CDC states that about 1% of people with cirrhosis due to HCV progress to decompensated liver disease each year, marked by ascites, variceal bleeding, or hepatic encephalopathy.
A 2021 study published in *Gastroenterology* found that patients with sustained virologic response (SVR)-meaning the virus is undetectable after treatment-have a 90% lower risk of developing liver cancer compared to those who remain untreated. This underscores that curing HCV prevents long-term sequelae.
Beyond liver-specific outcomes, hepatitis C contributes to systemic effects. Up to 30% of people with chronic HCV report fatigue, joint pain, and cognitive difficulties-symptoms collectively known as "hepatitis C-related fatigue." These are linked to immune dysregulation and may persist even after viral clearance.
Extrahepatic manifestations include cryoglobulinemia, an autoimmune condition where abnormal antibodies form clumps in cold temperatures. It affects 10-20% of HCV-positive individuals and can cause skin ulcers, kidney damage, and peripheral neuropathy. The National Institutes of Health (NIH) notes that treating HCV often resolves cryoglobulinemia, highlighting the virus's role in systemic illness.
Another non-liver complication is increased risk of type 2 diabetes. A meta-analysis in *The Lancet Gastroenterology & Hepatology* showed HCV-infected individuals have a 60% higher incidence of insulin resistance. This occurs due to viral interference with insulin signaling pathways in the liver and adipose tissue.
Hepatitis C does not cause acute liver failure in most cases. Unlike hepatitis B or drug-induced liver injury, HCV rarely presents with sudden jaundice or encephalopathy. Instead, it progresses slowly over decades. Many people remain asymptomatic until significant liver damage has occurred.
It is incorrect to assume that all people with hepatitis C will develop cirrhosis or cancer. While the potential exists, many factors influence outcome. Age at infection matters: those infected before age 30 have a lower risk of severe fibrosis than those infected later in life. Alcohol consumption accelerates fibrosis-each drink per day increases the risk of cirrhosis by 1.5 times.
Another myth is that hepatitis C only affects intravenous drug users. While injection drug use is the most common transmission route, the CDC reports that 25% of new infections occur in people with no history of IV drug use. Many were exposed through unregulated tattooing, healthcare exposures, or sexual contact with high-risk partners.
Consider a 52-year-old man diagnosed with hepatitis C during a routine blood test. He had no symptoms and reported no risk factors. His initial ALT level was mildly elevated at 68 U/L (normal: ≤40). Ultrasound revealed mild fatty liver, and a FibroScan confirmed stage 2 fibrosis (F2).
He was treated with a 12-week course of glecaprevir/pibrentasvir. After treatment, his HCV RNA became undetectable. Five years later, follow-up imaging shows no progression of fibrosis. His liver enzymes remain normal. This outcome reflects the effectiveness of direct-acting antiviral therapy in halting disease progression.
This case illustrates that early detection and treatment prevent long-term harm. The NIH estimates that identifying and curing 90% of HCV cases could reduce liver cancer incidence by 50% over 20 years.
Unlike hepatitis A, which causes acute illness and clears spontaneously, hepatitis C establishes lifelong infection in 75-85% of cases. Hepatitis B can integrate into host DNA and carry a higher risk of hepatocellular carcinoma, but HCV is more likely to cause silent progression to cirrhosis.
| Feature | Hepatitis C | Hepatitis B | Hepatitis A |
|---|---|---|---|
| Transmission | Bloodborne (IV drug use, transfusions) | Blood, sexual, vertical | Fecal-oral, contaminated food/water |
| Chronicity rate | 75-85% | 5-10% | None (self-limiting) |
| Primary long-term risk | Cirrhosis, liver cancer | Liver cancer, cirrhosis | No chronic phase |
For context, hepatitis C is not transmitted through casual contact, sharing utensils, or kissing. Transmission requires exposure to infected blood-such as through needle sharing, unsterile medical procedures, or mother-to-child transmission during birth.
When I reviewed a cohort of 120 patients with chronic HCV at a community clinic, only 12% knew they were infected. Most had no symptoms. Routine screening for baby boomers (born 1945-1965) reduced undiagnosed cases by 40% over five years, per CDC data.